Albert Bourla, Pfizer CEO (Michael Nagle/Bloomberg via Getty Images)
Pfizer shelves five mid- and early-stage programs
Pfizer is culling a handful of clinical programs, including trials in cancer and dermatology, it announced Tuesday.
The cuts include two …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
